Cited by 205Regulation of Appetite and ObesityDiabetes Treatment and ManagementPharmacology and Obesity Treatment

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

Open access

Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., Horowitz, M.·2005·Diabetologia

DOI 10.1007/s00125-005-1732-4

Open this paper in CoChat — free account Open PDF

Abstract

Aims/hypothesis Long-term trials in insulin-treated subjects with type 2 diabetes have shown that adjunctive treatment with the amylin analogue pramlintide reduces HbA(1)c levels and elicits weight loss. While amylin reduces food intake in rodents, pramlintide's effect on satiety and food intake in humans has not yet been assessed. Methods In this randomised, double-blind, placebo-controlled crossover study, 11 insulin-treated men with type 2 diabetes (age 60+/-9 years, BMI 28.9+/-4.8 kg/m(2)) and 15 non-diabetic obese men (age 41+/-21 years, BMI 34.4+/-4.5 kg/m(2)) underwent two standardised meal tests. After fasting overnight, subjects received single subcutaneous injections of either pramlintide (120 microg) or placebo, followed by a preload meal. After 1 h, subjects ate an ad libitum buffet meal. Energy intake and meal duration were measured, as were hunger ratings (using visual analogue scales), and plasma cholecystokinin, glucagon-like peptide-1 and peptide YY concentrations over time. Results Compared with placebo, pramlintide reduced energy intake in both the type 2 diabetes (Delta-202+/-64 kcal, -23+/-8%, p<0.01) and obese (Delta-170+/-68 kcal, -16+/-6%, p<0.02) groups, without affecting meal duration. Hunger and hormonal analyte profiles provided evidence that pramlintide may exert a primary satiogenic effect, independently of other anorexigenic gut peptides. Conclusions/interpretation The results indicate that enhanced satiety and reduced food intake may explain the weight loss observed in long-term pramlintide trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-005-1732-4

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger
Stunkard, A. J., & Messick, S. (1985) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(85)90010-8 · Cited by 4,687
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
Gutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 518
Pancreatic Polypeptide Reduces Appetite and Food Intake in Humans
Batterham, R. L., Le Roux, C. W., Cohen, M. A., Park, A. J., Ellis, S. M., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030630 · Cited by 496
Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 475
Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion
Rocca, A. S., & Brubaker, P. L. (1999) · Endocrinology · doi:10.1210/endo.140.4.6643 · Cited by 475
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468

Show all 49 references

Research works printed but not linked: 2

Mack C, Hoyt J, Moore C, Jodka C, Sams-Dodd F (2003) Sustained reduction in food intake and body weight in high fat-fed rats during 28-day amylin infusion. Diabetes 52[Suppl 1]:A389 (Abstract 1690-P)
World Health Organization (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series, 854. World Health Organization, Geneva

Sorted by citations

A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial
Fuller, N. R., Colagiuri, S., SCHOFIELD, D. J., Olson, A. D., Shrestha, R. N., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,127
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 470
Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
Ravussin, É., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 335
Self-citation
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Dual-process action of exercise on appetite control: increase in orexigenic drive but improvement in meal-induced satiety
King, N. A., Caudwell, P. P., Hopkins, M., Stubbs, J. R., Naslund, E., & Blundell, J. E. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27706 · Cited by 226
The obesity pipeline: current strategies in the development of anti-obesity drugs
Cooke, D., & Bloom, S. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 215
The role of gut hormones in the regulation of body weight and energy homeostasis
Karra, E., & Batterham, R. L. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.010 · Cited by 217
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179
Self-citation
Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study
Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178
Self-citation
CNS regulation of appetite
Harrold, J. A., Dovey, T. M., Blundell, J. E., & Halford, J. C. G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.007 · Cited by 209
The role of amylin in the control of energy homeostasis
Lutz, T. A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00703.2009 · Cited by 181
Amylinergic control of food intake
Lutz, T. A. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.04.001 · Cited by 172
Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C. (2008) · Diabetes Care · doi:10.2337/dc08-0029 · Cited by 172
Self-citation
A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes
Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O. (2006) · Diabetes Care · doi:10.2337/dc06-0042 · Cited by 166
Self-citation
Issues in Measuring and Interpreting Human Appetite (Satiety/Satiation) and Its Contribution to Obesity
Gibbons, C., Hopkins, M., Beaulieu, K., Oustric, P., & Blundell, J. E. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00340-6 · Cited by 185
Pharmacological management of appetite expression in obesity
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 142
Control of energy homeostasis by amylin
Lutz, T. A. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0905-1 · Cited by 139
Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study
Smith, S. R., Blundell, J. E., Burns, C. M., Ellero, C., Schroeder, B. E., Kesty, N. C., Chen, K. S., Halseth, A. E., Lush, C. W., & Weyer, C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00217.2007 · Cited by 131
Self-citation
Can We Really Close the Loop and How Soon? Accelerating the Availability of an Artificial Pancreas: A Roadmap to Better Diabetes Outcomes
Kowalski, A. J. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0031 · Cited by 128
Alterations in Gut Hormones After Laparoscopic Sleeve Gastrectomy
Dimitriadis, E., Daskalakis, M., Kampa, M., Peppe, A., Papadakis, J. A., & Melissas, J. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826e1846 · Cited by 122
New Drugs for Type 2 Diabetes Mellitus
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 122
GLP-1 and Amylin in the Treatment of Obesity
Jorsal, T., Rungby, J., Knop, F. K., & Vilsbøll, T. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0693-3 · Cited by 124
Amylin Modulates the Mesolimbic Dopamine System to Control Energy Balance
Mietlicki‐Baase, E. G., Reiner, D. J., Cone, J. J., Olivos, D. R., McGrath, L. E., Zimmer, D. J., Roitman, M. F., & Hayes, M. R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.180 · Cited by 118
Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin
Riddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc07-0589 · Cited by 116
Effects of dietary polyphenols on neuroregulatory factors and pathways that mediate food intake and energy regulation in obesity
Panickar, K. S. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200431 · Cited by 115
Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight
Mack, C. M., Soares, C. J., Wilson, J., Athanacio, J., Turek, V. F., Trevaskis, J. L., Roth, J. D., Smith, P. A., Gedulin, B. R., Jodka, C. M., et al. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.238 · Cited by 111
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 108
Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight.
Mack, C. M., Wilson, J., Athanacio, J., Reynolds, J. M., Laugero, K., Guss, S., Vu, C., Roth, J., & Parkes, D. (2007) · American Journal of Physiology. Regulatory Integrative and Comparative Physiology · doi:10.1152/ajpregu.00297.2007 · Cited by 115
Pramlintide and the treatment of diabetes: a review of the data since its introduction
Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 102
Metabolic stress, IAPP and islet amyloid
Montane, J., Klimek‐Abercrombie, A., Potter, K. J., Westwell‐Roper, C., & Bruce Verchere, C. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01657.x · Cited by 98
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 98
Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action
Gupta, P., Bala, M., Gupta, S. K., Dua, A., Dabur, R., Injeti, E. R., & Mittal, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.029 · Cited by 92
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
Hoogwerf, B. J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87
No Sex Difference in Body Fat in Response to Supervised and Measured Exercise
CAUDWELL, P., GIBBONS, C., HOPKINS, M., KING, N., FINLAYSON, G., & BLUNDELL, J. (2013) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31826ced79 · Cited by 86
Role of Amylin in Type 1 and Type 2 Diabetes
Hieronymus, L. B., & Griffin, S. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607642 · Cited by 87
Diabetes mellitus: new challenges and innovative therapies
Sena, C. M., Bento, C. F., Pereira, P., & Seiça, R. M. F. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0010-9 · Cited by 92
Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Hollander, P. A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.3.159 · Cited by 81
Current and Future Drug Targets in Weight Management
Witkamp, R. F. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0341-1 · Cited by 81
Combination Therapy with Amylin and Peptide YY[3–36] in Obese Rodents: Anorexigenic Synergy and Weight Loss Additivity
Roth, J. D., Coffey, T. S., Jodka, C. M., Maier, H., Athanacio, J., Mack, C. M., Weyer, C., & Parkes, D. G. (2007) · Endocrinology · doi:10.1210/en.2007-0898 · Cited by 79
Self-citation
Effects of palatability and learned satiety on energy density influences on breakfast intake in humans
Yeomans, M. R., WEINBERG, L., & JAMES, S. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.08.019 · Cited by 76
The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta‐analysis
Singh‐Franco, D., Pérez, A., & Harrington, C. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01337.x · Cited by 75
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
Singh‐Franco, D., Robles, G. I., & Gazze, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.04.005 · Cited by 75
Metabolic Phenotyping Guidelines: studying eating behaviour in humans
Gibbons, C., Finlayson, G., Dalton, M., Caudwell, P., & Blundell, J. E. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0020 · Cited by 74
New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?
Kennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 77
Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus
Caillon, L., Hoffmann, A. R. F., Botz, A., & Khemtémourian, L. (2015) · Journal of Diabetes Research · doi:10.1155/2016/5639875 · Cited by 74
Mediators of Amylin Action in Metabolic Control
Boyle, C. N., Zheng, Y., & Lutz, T. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082207 · Cited by 72
Pramlintide in the Treatment of Diabetes Mellitus
Edelman, S. V., Maier, H., & Wilhelm, K. (2008) · BioDrugs · doi:10.2165/0063030-200822060-00004 · Cited by 68
Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes
Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009) · Diabetes Care · doi:10.2337/dc09-0395 · Cited by 66
Amylin activates distributed CNS nuclei to control energy balance
Mietlicki‐Baase, E. G., & Hayes, M. R. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.01.013 · Cited by 65
Low‐dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal‐Weight Subjects
Chapman, I. M., Parker, B. A., Doran, S., Feinle‐Bisset, C., Wishart, J. M., Lush, C. W., Chen, K. S., LaCerte, C., Burns, C. M., McKay, R., et al. (2007) · Obesity · doi:10.1038/oby.2007.626 · Cited by 65
Self-citation
Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes
Pullman, J. R., Darsow, T., & Frías, J. P. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.203 · Cited by 65
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures
Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 75
Amylin-mediated control of glycemia, energy balance, and cognition
Mietlicki‐Baase, E. G. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.034 · Cited by 66
Prevention and Treatment of Type 2 Diabetes in Youth
Libman, I. M., & Arslanian, S. A. (2006) · Hormone Research in Paediatrics · doi:10.1159/000095981 · Cited by 62
The interaction of amylin with other hormones in the control of eating
Lutz, T. A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01670.x · Cited by 61
Drugs on the horizon for diabesity
Bailey, C. J. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0093-1 · Cited by 55
Creating the amylin story
Lutz, T. A. (2022) · Appetite · doi:10.1016/j.appet.2022.105965 · Cited by 59
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
Sonne, N., Karsdal, M. A., & Henriksen, K. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101109 · Cited by 60
Adjunct therapy for type 1 diabetes mellitus
Lebovitz, H. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.49 · Cited by 57
Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
Qiao, Y.-C., Ling, W., Pan, Y.-H., Chen, Y.-L., Zhou, D., Huang, Y.-M., Zhang, X.-X., & Zhao, H.-L. (2017) · Oncotarget · doi:10.18632/oncotarget.16008 · Cited by 54
Control of food intake and energy expenditure by amylin—therapeutic implications
Lutz, T. A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.13 · Cited by 53
Weak Satiety Responsiveness Is a Reliable Trait Associated with Hedonic Risk Factors for Overeating among Women
Dalton, M., Hollingworth, S., Blundell, J. E., & Finlayson, G. (2015) · Nutrients · doi:10.3390/nu7095345 · Cited by 52
Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide
Mack, C. M., Smith, P. A., Athanacio, J., Xu, K., Wilson, J., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01465.x · Cited by 51
Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 Diabetes
Marrero, D. G., Crean, J., Zhang, B., Kellmeyer, T., Gloster, M., Herrmann, K., Rubin, R. R., Fineberg, N. S., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc06-1026 · Cited by 49
Effects of Amylin on Eating and Adiposity
Lutz, T. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_10 · Cited by 48
The influence of physical activity on appetite control: an experimental system to understand the relationship between exercise-induced energy expenditure and energy intake
Caudwell, P., Gibbons, C., Hopkins, M., Näslund, E. B., King, N. A., Finlayson, G., & Blundell, J. E. (2011) · Proceedings of The Nutrition Society · doi:10.1017/s0029665110004751 · Cited by 49
A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet‐induced obese rats
Feigh, M., Henriksen, K., Andreassen, K. V., Hansen, C., Henriksen, J. E., Beck‐Nielsen, H., Christiansen, C., & Karsdal, M. A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01425.x · Cited by 45
Amylin and the regulation of appetite and adiposity
Roth, J. D. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835b896f · Cited by 45
Neuroendocrine Control of Food Intake
Butler, A. A., Trevaskis, J. L., & Morrison, C. D. (2007) · Springer eBooks · doi:10.1007/978-0-387-32164-6_1 · Cited by 44
It Takes Two to Tango: Combined Amylin/Leptin Agonism as a Potential Approach to Obesity Drug Development
Chan, J. L., Roth, J. D., & Weyer, C. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181b91911 · Cited by 44
Self-citation
Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats
Roth, J. D., Trevaskis, J. L., Wilson, J., Lei, C., Athanacio, J., Mack, C. M., Kesty, N. C., Coffey, T. S., Weyer, C., & Parkes, D. G. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.91 · Cited by 43
Self-citation
Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity
Dunn-Meynell, A. A., Foll, C. L., Johnson, M. D., Lutz, T. A., Hayes, M. R., & Levin, B. E. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00462.2015 · Cited by 43
Amylin
Hay, D. L. (2017) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13077 · Cited by 43
New Targets for Drug Treatment of Obesity
Valsamakis, G., Konstantakou, P., & Mastorakos, G. P. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104735 · Cited by 41
Pharmacological management of obesity an endocrine society clinical practice guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.23.59-63 · Cited by 42
Mechanisms of current therapies for diabetes mellitus type 2
Thulé, P. M. (2012) · AJP Advances in Physiology Education · doi:10.1152/advan.00094.2012 · Cited by 42
Weight Considerations in Pharmacotherapy for Type 2 Diabetes
Cheng, V., & Kashyap, S. R. (2010) · Journal of Obesity · doi:10.1155/2011/984245 · Cited by 40
Upper gastrointestinal function and glycemic control in diabetes mellitus
Chaikomin, R. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i35.5611 · Cited by 37
Pramlintide Lowered Glucose Excursions and Was Well-Tolerated in Adolescents with Type 1 Diabetes: Results from a Randomized, Single-Blind, Placebo-Controlled, Crossover Study
Chase, H. P., Lutz, K., Pencek, R., Zhang, B., & Porter, L. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.03.012 · Cited by 39
Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight
Karl, D. M., Philis‐Tsimikas, A., Darsow, T., Lorenzi, G. M., Kellmeyer, T., Lutz, K., Wang, Y., & Frías, J. P. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0013 · Cited by 38
Self-citation
Human Amylin: From Pathology to Physiology and Pharmacology
Ling, W., Huang, Y., Qiao, Y.-C., Zhang, X., & Zhao, H. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190328111833 · Cited by 37
Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk
Bays, H., Rodbard, H. W., Schorr, A. B., & González-Campoy, J. M. (2007) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-007-0021-6 · Cited by 36
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
Walker, C. S., Aitken, J. F., Amarsingh, G. V., Zhang, S., & Cooper, G. J. S. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01125-9 · Cited by 37
Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK
Beard, S. M., McCrink, L., Le, T. K., Garcia-Cebrian, A., Monz, B. U., & Malik, R. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253852 · Cited by 33
Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes
Maggs, D. G., Macdonald, I. A., & Nauck, M. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00737.x · Cited by 34
Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptine‐ QR (2型糖尿病治疗新药：第1部分.普兰林肽与溴隐亭‐QR)
Grunberger, G. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12034 · Cited by 32
Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes
Wysham, C., Lush, C. W., Zhang, B., Maier, H., & Wilhelm, K. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253537 · Cited by 32
Self-citation
Role of gastrointestinal hormones in feeding behavior and obesity treatment
Kairupan, T. S., Amitani, H., Cheng, K., Runtuwene, J., Asakawa, A., & Inui, A. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1118-4 · Cited by 29
Management of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
Effects of prior or concurrent food restriction on amylin-induced changes in body weight and body composition in high-fat-fed female rats
Roth, J. D., Hughes, H., Coffey, T. S., Maier, H., Trevaskis, J. L., & Anderson, C. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00395.2007 · Cited by 28
National survey of pediatric fever management practices among emergency department nurses.
Thomas, V., Riegel, B. J., Andrea, J., Murray, P., Gerhart, A. E., & Gocka, I. (1994) · PubMed · Cited by 27
Actions of feeding-related peptides on the mesolimbic dopamine system in regulation of natural and drug rewards
Dunigan, A. I., & Roseberry, A. G. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100011 · Cited by 28
A systematic review of the use of the Satiety Quotient
Fillon, A., Beaulieu, K., Mathieu, M.-E., Tremblay, A., Boirie‌, Y., Drapeau, V., & Thivel, D. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520002457 · Cited by 25
Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis
Kim, Y. J., Hwang, S. D., & Lim, S. K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00553 · Cited by 24

Authors: Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., & Horowitz, M.
Affiliations: Royal Adelaide Hospital (AU)
Corresponding author: Weyer, C.
ORCID: Parker, B.
Burns, C.
Horowitz, M.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2005-04-21
Volume: 48
Issue: 5
Pages: 838-848
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-005-1732-4
OpenAlex: W1965851116
Cited by: 205
References: 49
Citations by year: 2026: 5 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 7 · 2020: 9 · 2019: 5 · 2018: 2 · 2017: 6 · 2016: 4 · 2015: 11 · 2014: 5 · 2013: 9 · 2012: 11
FWCI: 8.21
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Topics: Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords: pramlintide, amylin analogues, satiety, dietary intake, obesity, type 2 diabetes, energy intake, hunger, cholecystokinin, glucagon-like peptide-1, peptide YY, weight loss, insulin-treated patients
MeSH terms: Adult, Amyloid, Energy Intake, Diabetes Mellitus, Type 2, Double-Blind Method, Energy Metabolism, Female, Humans, Hunger, Hypoglycemic Agents, Male, Middle Aged, Obesity, Placebos, Satiation, Body Mass Index, Diabetes Complications, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks